Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Implanon; Belgium: Implanon; Czech Republic: Implanon; Denmark: Implanon; Finland: Implanon; France: Implanon; Germany: Implanon; Greece: Implanon; Hungary: Implanon; Ireland: Implanon; Netherlands: Implanon; Portugal: Implanon; Slovakia: Implanon; Spain: Implanon; Sweden: Implanon; UK: Implanon.

North America

USA: Implanon.

Latin America

Brazil: Implanon; Mexico: Implanon.

Drug combinations

Etonogestrel and Ethinylestradiol


Etonogestrel: C~22~H~28~O~2~. Mw: 324.46. (1) 18,19-Dinor-17a-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-; (2) 13-Ethyl-17-hydroxy-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-3-one. CAS-54048-10-1 (1993).

Pharmacologic Category

Hormones and Synthetic Substitutes; Contraceptives; Progestins. (ATC-Code: G03AC08).

Mechanism of action

Active metabolite of desogestrel. Prevents pregnancy by suppressing ovulation, increasing viscosity of cervical mucous, and inhibiting endometrial proliferation.

Therapeutic use

Prevention of pregnancy. For use in women who request long-acting (up to 3 years) contraception.

Pregnancy and lactiation implications

Not for use during pregnancy. Use with caution during lactation.

Unlabeled use


Hypersensitivity to etonogestrel or any component of the formulation. Undiagnosed abnormal uterine bleeding. Active hepatic disease or malignant tumors. Active thrombophlebitis or thromboembolic disorders (current or history of same). Known or suspected breast carcinoma. Chronic potent hepatic enzyme inducers. Pregnancy.

Warnings and precautions

Ectopic pregnancy may occur (rarely). May increase risk of thromboembolism. Use with caution in renal impairment. Etonogestrel serum levels and contraceptive efficacy may be significantly decreased by potent hepatic enzyme inducer (use not recommended in women chronically taking hepatic enzyme inducers). Use with caution in overweight women. Not for use prior to menarche. Improper insertion may lead to unintended pregnancy or may cause difficult or impossible removal, and menstrual bleeding patterns are likely to be altered. Does not protect against HIV infection or other sexually-transmitted diseases. Use associated with a slight increase in frequency of breast cancer (studies not consistent). Use with caution in risk factors for coronary artery disease (may lead to increased risk of MI). May have a dose-related risk of vascular disease and hypertension. Use with caution in depression. Use with caution in diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes or renal dysfunction. May have a dose-related risk of gallbladder disease. May cause glucose intolerance. May affect serum triglyceride and lipoprotein levels (increased HDL-C, decreased LDL-C, and increased triglycerides; use with caution in familial lipoprotein metabolism defects). Use with caution in history of migraine. Estrogens may cause retinal vascular thrombosis (rarely). Risk of cardiovascular side-effects increases in women who smoke cigarettes, especially those over 35 years of age. Whenever possible, therapy should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with increased risk of thromboembolism or during periods of prolonged immobilization.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart